Acute Behavioral Change in a Patient with Parkinson Disease

Top tier (most likely, treat first):

1. Dopamine agonist–related psychosis/confusion. Pramipexole at 4.5 mg/day is a high dose for an older adult; visual hallucinations and somnolence are classic. The temporal link to dose and the absence of systemic illness support this.
2. Dementia with Lewy bodies (DLB) or Parkinson disease dementia (PDD). 9 years of motor disease plus fluctuating cognition and formed visual hallucinations fits PDD; the recent MMSE drop of 6 points in 6 months is faster than typical neurodegeneration alone, so a superimposed trigger is likely.

Second tier: 3. Delirium from a medical cause - the fall raises subdural hematoma; normal vitals and labs do not exclude it. Urinary tract infection and metabolic causes are less likely given normal labs but cannot be fully excluded. 4. Medication interaction - rasagiline plus pramipexole can compound dopaminergic excess; donepezil can cause vivid dreams and GI upset but less commonly formed hallucinations.

Lower probability: primary psychiatric illness (late-onset psychosis is uncommon), seizure, stroke.

Reasoning anchor: in a Parkinson patient with new hallucinations, the first question is always "what did we add or increase?" before invoking a new neurodegenerative diagnosis.

Step 1 - Reduce the most offending agent first. Taper and discontinue pramipexole (the dopamine agonist) before touching levodopa. Dopamine agonists carry the highest risk of impulse-control disorders, somnolence, and hallucinations, and removing them often resolves symptoms within days to weeks. Taper rather than stop abruptly to avoid dopamine agonist withdrawal syndrome (anxiety, dysphoria, pain, drug craving).

Step 2 - Reassess levodopa. If hallucinations persist after agonist withdrawal, reduce the levodopa dose or fractionate it. Do not stop levodopa abruptly - risk of akinetic crisis/NMS-like syndrome.

Step 3 - Image the brain. Noncontrast head CT (or MRI if available) to exclude subdural hematoma given the fall and the cognitive decline; this is a low-cost, high-consequence test.

Step 4 - Medications to avoid. Avoid typical antipsychotics (haloperidol) and most atypicals - they worsen parkinsonism and carry black-box mortality risk in elderly dementia. If pharmacologic control is needed, quetiapine (low dose) or clozapine (with CBC monitoring) are preferred. Avoid adding sedatives that worsen falls.

Step 5 - Reassess donepezil. It may help cognition in PDD/DLB, but if temporal relationship to its start is strong, consider holding it to see if symptoms improve. Document a cognitive baseline for longitudinal comparison.

Counseling points:

• If the delirium is driven by the dopamine agonist, substantial improvement is expected over 1–4 weeks after dose reduction, but recovery may be partial - delirium in a brain already affected by Parkinson disease often unmasks underlying cognitive impairment.
• Hallucinations can recur with any dopaminergic escalation or with intercurrent illness (infection, dehydration, surgery).
• Set expectations honestly: some patients return to baseline; others stabilize at a lower cognitive level and meet criteria for PDD.

Follow-up structure:

1. Phone or visit check within 1–2 weeks to assess hallucination frequency and motor function after the agonist taper.
2. Repeat cognitive screen at 3 months, off the acute delirium, to establish a new baseline.
3. Educate family on delirium triggers and red flags (fever, new focal deficit, worsening confusion, fall with head strike).
4. Coordinate with neurology for long-term medication strategy and consider a caregiver support referral.

Judgment being tested: recognizing that "the drug is the disease" in this population, avoiding antipsychotics that harm Parkinson patients, and framing prognosis without promising a full recovery.